
|Articles|February 2, 2006
FDA approves generic testosterone replacement gel
Watson Pharmaceuticals has received FDA approval on its abbreviated new drug application for a generic version of testosterone gel 1% CIII.
Advertisement
Watson Pharmaceuticals has received FDA approval on its abbreviated new drug application for a generic version of testosterone gel 1% CIII. The drug is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5







